Literature DB >> 31845145

Upper Gastrointestinal Perforations: A Possible Danger of Antibiotic Overuse.

Vijaya T Daniel1, Stephanie Francalancia2, Nili S Amir3, M Didem Ayturk4, Stacy B Sanders1, Jonathan R Wisler5, Courtney E Collins5, Doyle V Ward6, Catarina I Kiefe4, Beth A McCormick6, Heena P Santry7.   

Abstract

BACKGROUND: The role of changes in gut microflora on upper gastrointestinal (UGI) perforations is not known. We conducted a retrospective case-control study to examine the relationship between antibiotic exposure-a proxy for microbiome modulation-and UGI perforations in a national sample.
METHODS: We queried a 5% random sample of Medicare (2009-2013) to identify patients ≥ 65 years old hospitalized with UGI (stomach or small intestine) perforations using International Classification of Diseases diagnosis codes. Cases with UGI perforations were matched with 4 controls, each based on age and sex. Exposure to outpatient antibiotics (0-30, 31-60, 61-90 days) prior to case patients' index hospitalization admission data was determined with Part D claims. Univariate and multivariable regression analyses were performed to evaluate the effect of antibiotic exposure on UGI perforation.
RESULTS: Overall, 504 cases and 2016 matched controls were identified. Compared to controls, more cases had antibiotic exposure 0-30 days (19% vs. 3%, p < 0.001) and 31-60 days (5% vs. 2%, p < 0.001) prior to admission. In adjusted analyses, antibiotic exposure 0-30 days prior to admission was associated with 6.8 increased odds of an UGI perforation (95% CI 4.8, 9.8); 31-60 days was associated with 1.9 increased odds (95% CI 1.1, 3.3); and 61-90 days was associated with 3.7 increased odds (95% CI 2.0, 6.9).
CONCLUSIONS: Recent outpatient antibiotic use, in particular in the preceding 30 days, is associated with UGI perforation among Medicare beneficiaries. Exposure to antibiotics, one of the most modifiable determinants of the microbiome, should be minimized in the outpatient setting.

Entities:  

Keywords:  Antibiotics; Perforations; Upper gastrointestinal

Mesh:

Substances:

Year:  2019        PMID: 31845145      PMCID: PMC8133306          DOI: 10.1007/s11605-019-04473-w

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  40 in total

Review 1.  Modulating the human gut microbiome as an emerging therapeutic paradigm.

Authors:  Deepak K Rajpal; James R Brown
Journal:  Sci Prog       Date:  2013       Impact factor: 2.774

2.  Gut-derived sepsis occurs when the right pathogen with the right virulence genes meets the right host: evidence for in vivo virulence expression in Pseudomonas aeruginosa.

Authors:  J Alverdy; C Holbrook; F Rocha; L Seiden; R L Wu; M Musch; E Chang; D Ohman; S Suh
Journal:  Ann Surg       Date:  2000-10       Impact factor: 12.969

Review 3.  Interactions Between the Gastrointestinal Microbiome and Clostridium difficile.

Authors:  Casey M Theriot; Vincent B Young
Journal:  Annu Rev Microbiol       Date:  2015       Impact factor: 15.500

Review 4.  Rapidly expanding knowledge on the role of the gut microbiome in health and disease.

Authors:  M C Cénit; V Matzaraki; E F Tigchelaar; A Zhernakova
Journal:  Biochim Biophys Acta       Date:  2014-06-02

Review 5.  Alteration of the intestinal microbiota as a cause of and a potential therapeutic option in irritable bowel syndrome.

Authors:  J König; R J Brummer
Journal:  Benef Microbes       Date:  2014-09       Impact factor: 4.205

6.  Depletion of intestinal phosphate after operative injury activates the virulence of P aeruginosa causing lethal gut-derived sepsis.

Authors:  Jason Long; Olga Zaborina; Christopher Holbrook; Alexander Zaborin; John Alverdy
Journal:  Surgery       Date:  2008-08       Impact factor: 3.982

7.  Agent-based dynamic knowledge representation of Pseudomonas aeruginosa virulence activation in the stressed gut: Towards characterizing host-pathogen interactions in gut-derived sepsis.

Authors:  John B Seal; John C Alverdy; Olga Zaborina; Gary An
Journal:  Theor Biol Med Model       Date:  2011-09-19       Impact factor: 2.432

8.  Modeling the impact of antibiotic exposure on human microbiota.

Authors:  Jiangchao Zhao; Susan Murray; John J Lipuma
Journal:  Sci Rep       Date:  2014-03-11       Impact factor: 4.379

9.  The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing.

Authors:  Les Dethlefsen; Sue Huse; Mitchell L Sogin; David A Relman
Journal:  PLoS Biol       Date:  2008-11-18       Impact factor: 8.029

10.  Differential effects of antibiotic therapy on the structure and function of human gut microbiota.

Authors:  Ana Elena Pérez-Cobas; Alejandro Artacho; Henrik Knecht; María Loreto Ferrús; Anette Friedrichs; Stephan J Ott; Andrés Moya; Amparo Latorre; María José Gosalbes
Journal:  PLoS One       Date:  2013-11-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.